Key Highlights
- Eli Lilly to start late-stage trials next month for experimental obesity drug eloralintide.
- Patients in mid-stage trials lost up to 20.1% (21.3 kg) of their body weight.
- Analysts say the results put Lilly in the driver’s seat for amylin-based obesity treatments.
Pharmaceutical giant Eli Lilly has announced plans to move its experimental obesity drug eloralintide into late-stage clinical trials following highly encouraging results from a mid-stage study. The findings could position Lilly as a front-runner in the next wave of obesity treatments.
Lilly’s study enrolled 263 adults who were overweight with at least one obesity-related condition and without type 2 diabetes.
In the mid-stage trial, patients on the highest 9 mg dose of eloralintide achieved an average weight loss of 20.1% (21.3 kg), and those on the lowest 1 mg dose lost 9.5% (10.2 kg). In contrast, participants receiving a placebo lost just 0.2 kg on average at 48 weeks.
According to Lucy Codrington, an analyst at Jefferies, the data offer the strongest evidence yet that the amylin class can deliver GLP-1-like or superior weight loss.
Kevin Gade, chief operating officer at Lilly shareholder Bahl and Gaynor, said it puts Lilly in the “driver’s seat” for amylin treatments.
Analysts added that Lilly’s results set a new bar for other amylin-based drugs in development.
The positive data immediately shook up the shares of Zealand Pharma, which is developing its own amylin-based therapy, petrelintide, and fell 11% after Lilly’s announcement.
A New Approach Targeting the Amylin Pathway
The new drug, eloralintide, works by mimicking amylin, a natural hormone secreted by the pancreas that slows digestion and suppresses hunger. This mechanism differs from that of existing GLP-1-based treatments such as Lilly’s own Zepbound and rival Novo Nordisk’s Wegovy, both of which have driven the booming obesity drug market.
Beyond weight loss, trial participants also experienced improvements in metabolic and cardiovascular health, including reductions in waist circumference, blood pressure, cholesterol, and inflammation markers.
Reported side effects were mild to moderate, primarily gastrointestinal issues and fatigue, suggesting a favorable safety profile compared to some GLP-1 therapies.
Lilly Strengthens Its Position in the Expanding Obesity Drug Market
Industry experts say that if eloralintide’s Phase 3 results confirm these findings, it could become a cornerstone therapy in obesity management.
Eli Lilly has not yet disclosed the full trial timeline, but confirmed that late-stage trials will begin next month. This advances the company’s leadership in the global obesity drug market.
With eloralintide’s success, Eli Lilly is reinforcing its dominance in the healthcare industry, strengthening its multi-hormonal approach to weight loss and metabolic health, and setting the stage for the next generation of obesity drugs.